Brazil vs China: Tuberculosis patients who tested positive for HIV
Brazil
6,870 patients
in 2021
China
5,429 patients
in 2021
Brazil rank
13th
China rank
16th
Tuberculosis patients who tested positive for HIV over time
- Brazil
- China
How they compare
Brazil currently reports 6,870 patients against 5,429 patients in China, a difference of 1,441 patients.
That makes Brazil's figure about 1.3 times China's.
The two have swapped places 4 times across 16 shared years of data; in 2006 it was Brazil ahead.
Brazil ranks 13th and China ranks 16th of 201 countries.
Brazil has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Brazil | China | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 8,005 patients | 1,748 patients | 6,258 patients | Brazil |
| 2010s | 8,556 patients | 6,070 patients | 2,486 patients | Brazil |
| 2020s | 6,738 patients | 5,752 patients | 985.5 patients | Brazil |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher tuberculosis patients who tested positive for hiv, Brazil or China?
- Brazil, at 6,870 patients against 5,429 patients in China as of 2021.
- What is the difference in tuberculosis patients who tested positive for hiv between Brazil and China?
- 1,441 patients, with Brazil ahead.
- How many years of comparable data are there for Brazil and China?
- 16 years are reported by both, from 2006 to 2021.
- How do Brazil and China rank globally for tuberculosis patients who tested positive for hiv?
- Brazil ranks 13th and China ranks 16th of 201 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026); Population based on various sources (2024) – with minor processing by Our World in Data, published as Tuberculosis patients who tested positive for HIV. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Estimated number of tuberculosis (new and relapsed) patients that tested positive for HIV.